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Abstract 
Background: High-grade foci (grade 3 according to Broder’s grading system) are sometimes detected in low-grade 
(grade 1 and 2) central osteosarcoma. The aim of this study was to retrospectively evaluate the clinical outcome in 
patients upgraded to high grade (grade 3) after a first diagnosis of low-grade osteosarcoma, following the detection 
of high-grade areas (grade 3) in the resected specimen.
Methods: Of the 132 patients with a diagnosis of low-grade central osteosarcoma at surgical biopsy at our Institute, 
33 patients were considered eligible for the study.
Results: Median age was 37 (range 13–58 years). Location was in an extremity in 29 patients (88 %). Post-operative 
chemotherapy was given in 22 (67 %) patients. Follow-up data were available for all patients, with a median observa-
tion time of 115 months (range 4–322 months). After histological revision, areas of high-grade (grade 3) osteosarcoma 
accounting for less than 50 % of the tumor were found in 20 (61 %) patients, whereas the majority of the tumor was 
composed of a high-grade (grade 3) component in 13 (39 %) patients. In the 20 cases of low-grade osteosarcoma 
with high-grade foci (grade 3) in less than 50 % of the tumor, 9 patients did not receive adjuvant chemotherapy; 
only one of them died, of unrelated causes. In the adjuvant chemotherapy group (11 out of 20 patients), one patient 
developed multiple lung metastases and died of disease 39 months after the first diagnosis. In the other 13 cases of 
low-grade osteosarcoma with high-grade foci (grade 3) in more than 50 % of the tumor, 12 patients received adjuvant 
chemotherapy: 2 had recurrence, 4 developed multiple lung metastases and 3 died of disease. The only patient who 
did not receive chemotherapy is alive without disease 232 months after complete surgical remission.
Conclusion: Our data indicate that patients with a diagnosis of low-grade osteosarcoma where the high-grade 
(grade 3) component is lower than 50 % of the resected specimen, may not require chemotherapy, achieving high 
survival rates by means of complete surgical resection only.
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Background
The grading of malignant bone tumors has tradition-
ally been based on a combination of histologic diagnosis 
and Broder’s grading system, which assesses cellularity 
and degree of anaplasia [1]. The 7th edition of the AJCC 
Cancer Staging Manual recommends a 4 grade system, 
with grades 1 and 2 being considered “low-grade” and 
grades 3 and 4 “high-grade”. The World Health Organiza-
tion endorses the use of a two-tier system designating an 
osteosarcoma as low-grade (grades 1 and 2 in a four-tier 
system) or high-grade (grades 3 and 4 in a four-tier sys-
tem) [2].
Histologic grading of osteosarcoma has an important 
impact on clinical outcome: the risk of distant metasta-
ses is low in grade 1–2 (low-grade) and high in cases of 
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grade 3–4 (high-grade) osteosarcoma, making chemo-
therapy mandatory in patients with a diagnosis of grade 
3–4 (high-grade) osteosarcoma [3, 4].
Low-grade central osteosarcoma is an uncommon 
variant, accounting for approximately 1–2 % of all oste-
osarcomas composed of low-grade, mostly fibroblas-
tic, osteogenic proliferation featuring mild cytological 
atypia [5, 6]. The low-grade central osteosarcoma series 
published in the literature report an incidence of areas 
of high-grade osteosarcoma ranging between 10 and 
36 % of cases [3–5, 7–12]. Some authors regard the high-
grade component of low-grade central osteosarcoma as a 
separate entity from conventional high-grade osteosar-
coma, and consider it a form of morphologic progression 
(dedifferentiation) of a low-grade osteosarcoma [7–9, 11, 
12]. While this distinction is controversial and not uni-
formly accepted, it appears that low-grade tumors with 
focal high-grade progression actually behave differently 
than their conventional high-grade counterparts [7–9, 
11]. Unfortunately there are no established criteria (such 
as the percentage of the overall tumor with a high-grade 
component) to categorize these tumors as typical high-
grade (grade 3–4) osteosarcoma [3–5]. In principle, the 
presence of any high-grade area in a low-grade lesion 
makes the tumor high-grade, thereby prompting sys-
temic adjuvant treatment [13–15]. Nevertheless, there is 
little data in support of such therapeutic approach, and 
it is not well established whether low-grade (grade 1–2) 
central osteosarcoma with areas of high-grade (grade 
3) osteosarcoma actually differs from high-grade (grade 
3–4) osteosarcoma, with regard to rates of local recur-
rence, metastasis, and survival.
The aim of this study was to retrospectively evaluate 
the clinical outcome in patients who, after a first diagno-
sis of low-grade central osteosarcoma based on surgical 
biopsy, were upgraded to high-grade (grade 3) osteosar-
coma following evaluation of the surgical specimen at 
resection.
Methods
The medical records were retrieved of a consecutive 
series of patients diagnosed and treated for low-grade 
osteosarcoma (grade 1–2 according to Broder’s grading 
system) at the Rizzoli Institute, Bologna, Italy, between 
January 1981 and June 2014 (Fig.  1a, b). The resected 
specimens and radiological imaging were reviewed. No 
patients received preoperative chemotherapy. A state-
ment on consent to use the data for scientific purposes 
was obtained from all patients. Inclusion criteria were: 
(a) availability of the histologic slides of both the biopsy 
and surgical specimens, in which systematic mapping 
of the entire tumor featured a low-grade osteosarcoma 
according to the protocol for the examination of bone 
tumor specimens [16]. Three pathologists (A.R., M.G., 
A.D.T.) independently reviewed the slides stained with 
hematoxylin and eosin, evaluating diagnosis, subtype, 
and grade. On the basis of the predominant morphol-
ogy of the neoplastic cells and quality of the intercel-
lular matrix, osteosarcomas were classified in surgical 
specimens by the following subtypes: osteoblastic, chon-
droblastic and fibroblastic. Tumours were graded accord-
ing to the 4-tiered Broder’s grading system by assessing 
cellularity and degree of atypia [1]. Where high-grade 
(grade 3) areas were detected (defined as the presence of 
increased cellularity, absence of the typical architectural 
pattern of growth of low-grade osteosarcoma and higher 
nuclear atypia), tumor maps were examined and the per-
centage of high-grade (grade 3) areas scored (Fig. 2a–c).
After definitive surgical treatment, the use of postoper-
ative chemotherapy was mainly based on clinical experi-
ence, as no specific guidelines were available. For patients 
younger than 40  years, the chemotherapy regimen was 
based on the protocol adopted at the time for non meta-
static osteosarcoma. The remaining patients received a 
chemotherapy regimen without methotrexate and usu-
ally including doxorubicin, cisplatin and ifosfamide. All 
patients, regardless of the use of adjuvant chemotherapy, 
were followed up every 2–3 months in the first 2–3 years 
and then every 4–6  months. Survival analysis was per-
formed according to Kaplan–Meier. All analyses were 
performed using Stata/SE statistical software (version 
10.0; StataCorp LT, College Station, TX, USA).
Results
Of the 132 patients with a diagnosis of low-grade (grade 
1 and 2) osteosarcoma at surgical biopsy, 33 patients were 
considered eligible for the study. The clinical and patho-
logical features are summarized in Table  1. The median 
age was 37 years (range 13–58 years) with a slight preva-
lence of females. Most of the tumours were located in the 
extremities. The majority of the patients (26 cases, 79 %) 
had a diagnosis of fibroblastic osteosarcoma (of these, 4 
cases had the fibrous dysplasia-like variant), followed by 
osteoblastic osteosarcoma (5 cases, 15  %) and chondro-
blastic osteosarcoma (2 cases, 6 %). All patients were sur-
gically treated with wide surgical margins. Twenty-two 
(67 %) patients received adjuvant chemotherapy.
Follow-up data were available for all patients with 
a median observation time of 115  months (range 
4–322  months). Twenty (61  %) patients showed areas 
of high-grade (grade 3) osteosarcoma accounting for 
less than 50 % of the tumor, whereas 13 (39 %) patients 
showed a high-grade (grade 3) component in the major-
ity of the tumor (Table 1).
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Low‑grade osteosarcoma with high‑grade foci (grade 3 
in less than 50 % of the tumor: 20 patients)
None of the patients belonging to this group showed 
metastatic lesions at the staging workup. Adjuvant 
chemotherapy was not given to 9 (45  %) patients. One 
patient (case 8) showed a local recurrence in the soft tis-
sue 53  months after surgical resection. Recurrence was 
surgically removed and morphologically it was associ-
ated with progression to a higher grade (grade 4, fibro-
blastic and osteoblastic osteosarcoma). Therefore the 
patient received adjuvant chemotherapy and at the last 
follow-up (232  months after the surgical bone resec-
tion) is alive without disease. Another patient (case 18) 
developed a single bone metastasis in the thoracic verte-
bra, which was surgically removed. Morphologically the 
vertebral lesion showed the same features as the primi-
tive osteosarcoma (grade 2 fibroblastic osteosarcoma, 
fibrous dysplasia-like variant). The patient started adju-
vant chemotherapy and at the last follow-up (57 months 
after the surgical bone resection) is alive without disease. 
Another patient of this group (case 12) died of unrelated 
causes. The remaining patients are disease-free at last fol-
low-up. Adjuvant chemotherapy was given to 11 (55  %) 
patients. One patient (case 2) developed multiple lung 
metastases 13  months after surgery. Histologically, the 
lung metastases were diagnosed as grade 4 osteoblastic 
Fig. 1 a, b A low grade (grade 2) fibroblastic osteosarcoma, fibrous 
dysplasia-like variant (case no. 18)
Fig. 2 a–c An example of a case with high-grade (grade 3) areas 
characterized by the presence of increased cellularity, lack of typical 
architectural pattern of growth of low grade osteosarcoma and 
higher nuclear atypia
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osteosarcoma. After surgical resection of the lung metas-
tases the patient underwent second line chemotherapy 
and died of disease 39 months after the first diagnosis.
Overall 18 (90  %) of the 20 patients with an area of 
high-grade (grade 3) osteosarcoma accounting for less 
than 50 % of the tumor were alive without disease, none 
of the patients who did not receive adjuvant chemother-
apy died of disease. The median observation time was 
109 months (from 29 to 284 months). The probability of 
evidence-free survival and overall survival at 5 years was 
88 % (95 % CI 72–100 %) and 95 % (95 % CI 84–100 %), 
respectively.
Table 1 The clinical and  pathological features of  33 cases of  low-grade central osteosarcoma with  areas of  high-grade 
(grade 3)













1 56/F Distal femur 2 Osteoblastic No NED (55)
2 39/M Proximal humerus 4 Fibroblastic 
(fibrous 
dysplasia-like)
Yes Lung (13) DOD (39)
3 19/M Distal femur 4 Osteoblastic No NED (157)
4 34/F Proximal humerus 4 Fibroblastic No NED (120)
5 35/F Distal femur 4 Fibroblastic Yes NED (225)
6 44/M Proximal humerus 4 Fibroblastic Yes NED (56)
7 23/M Distal femur 4 Fibroblastic Yes NED (69)
8 25/F Distal femur 4 Fibroblastic No Yes (53) NED (284)




10 22/F Proximal femur 9 Fibroblastic Yes NED (132)
11 32/F Proximal humerus 9 Fibroblastic No NED (109)
12 58/F Proximal femur 11 Fibroblastic No DOC (136)
13 27/M Proximal tibia 16 Fibroblastic No NED (231)
14 45/M Distal tibia 16 Fibroblastic Yes NED (45)
15 24/F Distal femur 16 Osteoblastic Yes NED (45)
16 41/M Proximal tibia 16 Osteoblastic No NED (89)
17 55/F Pelvis 31 Osteoblastic Yes NED (33)
18 28/M Proximal humerus 31 Fibroblastic 
(fibrous 
dysplasia-like)
No Bone thoracic 
vertebra (51)
NED (57)
19 50/M Distal femur 35 Fibroblastic No NED (262)
20 21/M Distal femur 40 Fibroblastic Yes NED (151)
21 42/M Proximal femur 51 Fibroblastic Yes Yes (21) Lung (46; 65) DOD (108)




23 59/M Proximal humerus 51 Fibroblastic Yes Lung (37; 85) NED (137)
24 35/F Distal ulna 51 Fibroblastic Yes NED (4)
25 25/M Lumbar vertebra 51 Fibroblastic Yes NED (10)
26 24/M Proximal humerus 51 Osteoblastic Yes NED (65)
27 40/M Proximal tibia 81 Fibroblastic Yes Lung (10) DOD (32)
28 53/F Proximal tibia 81 Fibroblastic Yes Yes (2) DOD (5)
29 46/F Distal femur 81 Fibroblastic Yes Lung (14;38;50) NED (132)
30 49/F Distal femur 81 Chondroblastic Yes NED (164)
31 42/F Pelvis 81 Fibroblastic Yes NED (27)
32 20/F Proximal femur 81 Chondroblastic No NED (250)
33 48/F Distal femur 81 Fibroblastic Yes NED (322)
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Low‑grade osteosarcoma with high‑grade foci (grade 3) 
in more than 50 % of the tumor (13 patients)
Twelve patients received adjuvant chemotherapy. Of 
these, two patients had recurrent disease in the soft tis-
sues (cases 21, 28) after 2 and 21  months of follow-up, 
respectively, and one of them (case 28) died of disease 
5 months after the surgical resection. Four patients devel-
oped lung metastases (cases 21, 23, 27, 29) after a mean 
follow-up of 27 months (range 10–46 months). Three of 
these 4 patients (cases 21, 23, 29) developed other multi-
ple lung metastases following the first lung metastasecto-
mies. Both the two recurrences and lung metastases were 
histologically associated with progression to a higher 
grade (grade 4) osteosarcoma.
Two of 4 patients with lung metastases (cases 21, 27) 
died of disease after 108 and 32 months, respectively. The 
patient (case 32) who did not receive chemotherapy is 
alive without disease 232 months after complete surgical 
remission.
Overall 10 (77  %) of the 13 patients with areas of 
high-grade (grade 3) osteosarcoma accounting for more 
than 50  % of the tumor were alive without disease, 5 
(38.5  %) patients experienced recurrent disease, with 
distant metastases in 4 and local recurrence in only one 
patient. The median observation time was 120 months 
(from 4 to 322  months). The probability of evidence-
free survival and overall survival at 5  years was 68  % 
(95  % CI 42–94  %) and 83  % (95  % CI 61–100  %), 
respectively.
Discussion
The grading of osteosarcoma is based on morphologic 
observation of a set of parameters that have proved rel-
atively reproducible [1, 2, 4]. Some discrepancies are 
unavoidable when comparing biopsy material with the 
corresponding surgical specimen, in which variable 
amounts of higher grade malignancy can be seen. It is 
our experience that areas of high-grade (grade 3) osteo-
sarcoma can be found in patients with a bioptic diagnosis 
of low-grade (grade 1–2) osteosarcoma, even when the 
biopsy was obtained from the site showing the greatest 
aggressiveness on imaging studies [6–8, 17, 18].
Interestingly, the group of patients forming the study 
population exhibit clinical features that differ from those 
observed in patients with conventional high-grade oste-
osarcoma. The age of our patients was higher than the 
age reported for classic osteosarcoma, with most of the 
patients being adults [1, 2, 4]. Another observed differ-
ence was the histologic subtype. It is well known that 
osteoblastic osteosarcoma is the most frequent subtype 
[1, 2, 4], whereas most low-grade osteosarcomas with 
high-grade areas were fibroblastic osteosarcoma.
High-grade dedifferentiation or progression to a higher 
grade in low-grade central osteosarcoma represents an 
exceedingly rare event, which can be seen in the primary 
tumor, but more commonly in recurrences [7–12, 19]. 
Our series reports a 25  % rate of progression to high-
grade (grade 3) osteosarcoma (33/132 cases), which to 
some extent overlaps with the range of 10–36 % of cases 
reported in the literature [3–5, 7–12]. Previous reports 
have documented the association between inadequate 
surgical resection, local recurrence, and morphologic 
progression to higher grade, which was associated with a 
poor prognosis [7, 8, 19]. While surgery alone is deemed 
adequate for low-grade central osteosarcoma, even in the 
absence of published guidelines, the addition of chemo-
therapy is being suggested as an option for those patients 
featuring areas of histologic progression (also defined by 
some authors as dedifferentiation) [7–15, 19].
This study shows that the presence of areas of high-
grade (grade 3) progression in patients with low-grade 
osteosarcoma does not by itself imply biological systemic 
aggressiveness. Furthermore we have shown a correlation 
between the percentage of high-grade (grade 3) areas and 
risk of metastatic spread. In our retrospective analysis, 
those patients with low-grade osteosarcoma with a high-
grade (grade 3) component of less than 50 % of the tumor 
did in fact have a very high probability of survival regard-
less of the use of adjuvant chemotherapy. By contrast, 
the clinical behaviour of tumors featuring a high-grade 
(grade 3) osteosarcoma component greater than 50  % 
overlaps with that reported for conventional high-grade 
osteosarcoma [1, 2, 4, 17, 18].
In surgical pathology it is broadly accepted that 
the grade of any tumor is based on the highest grade 
observed in the surgical specimen [20]. Our study seems 
to suggest that this general rule cannot be applied sys-
tematically to all osteosarcomas.
The standard treatment of high-grade (grade 3–4) oste-
osarcoma is surgical removal of the tumor and adjuvant 
(or neo-adjuvant) chemotherapy [3, 13–15]. A pathology 
report describing areas of high-grade (grade 3–4) osteo-
sarcoma would currently represent the rationale for the 
use of chemotherapy [3, 13–15].
Conclusion
Our data indicate that not all patients with a diagnosis of 
osteosarcoma featuring a high-grade (grade 3) compo-
nent would benefit from systemic treatment. In particu-
lar, in patients with small foci with high-grade (grade 3) 
progression or in whom the high-grade (grade 3) com-
ponent is less than 50  % of the resected specimen at 
tumour map examination, high survival rates can only be 
achieved by means of complete surgical resection.
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